Docetaxel-structure (2ad4f265 675e 47bf A2fa 57d9266a6dda 01)
Docivyx Injection, Solution
Product Images NDC 83831-101
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docivyx (NDC 83831-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Avyxa Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Tax316 Disease-free Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 02)
Image (2ad4f265 675e 47bf A2fa 57d9266a6dda 03)
Figure 3: Tax317 Survival K-m Curves (DOCIVYX 75 mg/m2 Versus Best Supportive Care)
This text provides information on cumulative probability related to survival time in months. The log-rank p-value is reported as 0.010, indicating a significant difference.*
Figure 4: Tax320 Survival K-m Curves (DOCIVYX 75 mg/m2 Versus Vinorelbine or Ifosfamide Control)
This information presents the cumulative probability of overall survival at different time points (3, 6, 9, 12, 15, and 18 months) as well as the Log-rank p-value (0.13) for comparison.*
Figure 5: Tax327 Survival K-m Curves (2ad4f265 675e 47bf A2fa 57d9266a6dda 06)
Survival probability based on survival time in months (9, 12, 15, 18, 21) is provided in the data. The corresponding survival time in months seems to be 24, 27, and 30.*
Figure 6: Gastric Cancer Study (tax325) Time To Progression K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 07)
Figure 7: Gastric Cancer Study (tax325) Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 08)
This data provides the survival probability in percentage at different survival times measured in months. The table shows the chances of survival at 15, 18, 21, 24, and 27 months.*
Figure 8: Tax323 Progression-free Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 09)
Progression Free Survival Probability (%) for different time points (in months).*
Figure 9: Tax323 Overall Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 10)
Figure 10: Tax324 Overall Survival K-m Curve (2ad4f265 675e 47bf A2fa 57d9266a6dda 11)
This text appears to be a table showing survival probabilities over time for two treatment groups (TPF and PF) along with the number of patients at risk and survival time in months for each time point. The data presented includes survival probability percentages, number of patients at risk, and survival time in months. This information could be useful for analyzing and comparing the effectiveness of the two treatments over time.*
Docivyx (docetaxel) Injection, 20 mg/2 mL -vial Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 12)
This is the product information for Docetaxel Injection, which comes in a 20 mg per 2 mL (10 mg per mL) single-dose vial for intravenous infusion only. The National Drug Code (NDC) for this product is 83831-101-02. It is recommended to discard any unused portion of the medication.*
Docivyx (docetaxel) Injection, 20 mg/2 mL -carton Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 13)
This text is a description of Docivyx (Docetaxel) Injection, a medication that is ready to add to an infusion solution. It contains 10 mg of Docetaxel, 380 mg of SBECD, 160 mg of Polyethylene Glycol 300 NF, 40 mg of PVP Ky, and other ingredients. The recommended dosage should be followed as per prescribing information. It is a hazardous drug and should be kept out of reach of children, stored between 2°C to 25°C, and protected from light. The product is manufactured for Avyxa Pharma, LLC, USA, and is made in China. Each vial contains 20 mg per 2 mL and should be used for intravenous infusion only. Unused portions should be discarded.*
Docivyx (docetaxel) Injection, 80 mg/8 mL -vial Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 14)
Docivyx (docetaxel) Injection, 80 mg/8 mL -carton Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 15)
This is a description of Docivyx (Docetaxel) Injection, a medication ready to be added to an infusion solution for intravenous infusion. Each mL contains 10 mg Docetaxel, 380 mg SBECD, 160 mg Polyethylene Glycol 300 NF, 40 mg PVP Kiz, 220 mg Dehydrated Alcohol USP, and Citric Acid Anhydrous USP. The recommended dosage should be followed as per prescribing information. It is important to keep this hazardous drug out of reach of children, and to store it between 2°C to 25°C (36°F to 77°F) while protecting it from light. The medication comes in an 8 mL single-dose vial that should be discarded if unused. The product is manufactured for Avyxa Pharma, LLC, in New Jersey, USA, and has been made in China. It includes NDC 83831-102-08 and J Code J9172.*
Docivyx (docetaxel) Injection, 160 mg/16 mL -vial Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 16)
Docivyx (docetaxel) Injection, 160 mg/16 mL -carton Label (2ad4f265 675e 47bf A2fa 57d9266a6dda 17)
This text appears to be related to a medication called "Docetaxel Injection". The medication is in a 16 mL single-dose vial and contains 10 mg of Docetaxel along with other components. It is intended for intravenous infusion and should be stored at temperatures between 2°C to 25°C. It is important to keep this hazardous drug out of reach of children and to discard any unused portion. The prescribing information should be referred to for recommended dosages.*
Image (2ad4f265 675e 47bf A2fa 57d9266a6dda 187 2)
Image (2ad4f265 675e 47bf A2fa 57d9266a6dda 213 2)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
